|
|
Vaccine Detail
|
AG0302-COVID19 |
| Vaccine Information |
- Vaccine Name: AG0302-COVID19
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: AnGes, Inc.
- Vaccine Ontology ID: VO_0005322
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Immune Response: A cellular immune response was observed in some subjects after AG0302-COVID19 intradermal inoculation (Nakagami et al,, 2022)
- Description: AG0302-COVID19 is under clinical trial now (NCT04655625; Nakagami et al,, 2022)
Phase II/III: NCT04655625
Age subgroups: 18 years and above
Location: Japan
|
| References |
Nakagami et al,, 2022: Hironori Nakagami, Hiroki Hayashi , Jiao Sun , Yuka Yanagida , Takako Otera , Futoshi Nakagami , Shigeto Hamaguchi , Hisao Yoshida , Hideo Okuno , Shota Yoshida , Ryo Nakamaru , Serina Yokoyama , Taku Fujimoto , Kazuhiro Hongyo , Yukihiro Akeda , Ryuichi Morishita , Kazunori Tomono , Hiromi Rakugi. Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults. . 2022; ; . [PubMed: 36146505].
NCT04655625: Clinical trial for vaccine AG0302-COVID19 [https://clinicaltrials.gov/ct2/show/NCT04655625]
|
|
